World Hepatitis Day is recognized annually on July 28th, the birthday of Dr. Baruch Blumberg (1925–2011). Dr. Blumberg discovered the hepatitis B virus in 1967 and two years later developed the first hepatitis B vaccine. Read more about the latest developments in viral hepatitis treatment, including the approval of two new drug therapies.

First All-Oral Therapy for Genotype 4 HCV Approved

AbbVie announced that the FDA has approved Technivie (ombitasvir, paritaprevir, ritonavir) tablets in combination with ribavirin for the treatment of adults with genotype 4 chronic HCV infection who do not have cirrhosis. Read More
New Oral Tx for Genotype 3 Hep C Infection Approved

Bristol-Myers Squibb announced that the FDA has approved Daklinza (daclatasvir) in combination with sofosbuvir for the treatment of chronic HCV genotype 3 infection. Read More
Olysio sNDA Submitted for Labeling Update

Janssen Therapeutics announced the submission of a supplemental New Drug Application (sNDA) to the FDA to update the label for once-daily, all-oral Olysio (simeprevir) in combination with sofosbuvir for adults with genotype 1 chronic HCV infection with or without cirrhosis. Read More
First Study Tests New Combo Tx for HCV/HIV Co-Infection

Researchers from the University of California, San Diego School of Medicine reported a new combination therapy that effectively treated HCV in patients co-infected with HIV. Read More
HCV Vastly Underreported in the United States

New cases of hepatitis C are drastically underreported to federal officials, according to a recent case series and chart review. Read More
HCV Treatment Guidelines Updated With Antivirals

The AASLD announced that an update to the Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 has been published. Read More
Intradermal HBV Vaccine Appears Safe, Effective for Intramuscular Nonresponders

For intramuscular HBV vaccine nonresponders, intradermal vaccine administration seems efficacious and safe in a new study. Read More
No Virologic Failures With Combo HCV Tx in Study

AbbVie announced results from the Phase 3b TURQUOISE-III study with Viekirax (ombitasvir/paritaprevir/ritonavir) plus Exviera (dasabuvir) without ribavirin (RBV) in genotype 1b chronic HCV infected adult patients with compensated liver cirrhosis. Read More
Antiviral Prevents Mother-to-Infant Transmission of HBV in Study

A recent study showed that nearly all pregnant women with HBV taking telbivudine had undetectable levels of HBV DNA in cord blood, with no severe adverse events or complications observed in women or infants. Read More
FDA Accepts Grazoprevir/Elbasvir NDA for Chronic HCV

The FDA has accepted the New Drug Application (NDA) for grazoprevir/elbasvir (Merck) for the treatment of adult patients infected with chronic HCV genotypes 1, 4, or 6. Read More